Search

Your search keyword '"Voest, Emile"' showing total 1,373 results

Search Constraints

Start Over You searched for: Author "Voest, Emile" Remove constraint Author: "Voest, Emile"
1,373 results on '"Voest, Emile"'

Search Results

1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

2. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

3. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

4. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

6. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)

9. A pan-cancer analysis of the microbiome in metastatic cancer

10. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics

11. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

12. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

13. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity

14. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

16. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

18. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

19. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

20. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

22. Delivering precision oncology to patients with cancer

23. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

24. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol

30. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma:Results From the Drug Rediscovery Protocol

31. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol

32. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

33. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer

34. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer

35. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer:Results from the drug rediscovery protocol (DRUP)

36. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

39. Facilitating a culture of responsible and effective sharing of cancer genome data

40. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

41. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics

42. Caring for patients with cancer in the COVID-19 era

43. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

45. Pan-cancer whole-genome analyses of metastatic solid tumours

47. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

48. Precision cancer medicine: Concepts, current practice, and future developments

Catalog

Books, media, physical & digital resources